



# HHS Public Access

Author manuscript

*Crit Care Med.* Author manuscript; available in PMC 2023 March 26.

Published in final edited form as:

*Crit Care Med.* 2022 October 01; 50(10): 1449–1460. doi:10.1097/CCM.0000000000005626.

## Awareness with paralysis among critically ill emergency department patients: a prospective cohort study

**Brian M. Fuller, MD, MSCI, FCCM,**

Departments of Anesthesiology and Emergency Medicine, Division of Critical Care, Washington University School of Medicine in St. Louis, St. Louis, MO 63110

**Ryan D. Pappal, BS, BA, NRP,**

Washington University School of Medicine in St. Louis, St. Louis, MO 63110

**Nicholas M. Mohr, MD, MS,**

Departments of Emergency Medicine and Anesthesiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 200 Hawkins Drive, 1008 RCP, Iowa City, IA 52242

**Brian W. Roberts, MD, MSc,**

Department of Emergency Medicine, Cooper University Hospital, One Cooper Plaza, K152, Camden, NJ

**Brett Faine, PharmD, MS,**

Departments of Emergency Medicine and Pharmacy, Roy J. and Lucille A. Carver College of Medicine, University of Iowa College of Pharmacy, 200 Hawkins Drive, 1008 RCP, Iowa City, IA 52242

**Julianne Yeary, PharmD, BCCCP,**

Clinical Pharmacy Specialist –Emergency Department, Charles F. Knight Emergency and Trauma Center, Barnes Jewish Hospital, 1 Barnes Jewish Hospital Plaza, St. Louis, MO 63110

**Thomas Sewatsky, MD,**

Department of Emergency Medicine, Cooper University Hospital, One Cooper Plaza, K152, Camden, NJ

---

Corresponding Author: Brian M. Fuller, MD, MSCI, FCCM, Washington University School of Medicine in St. Louis, Campus Box 8054, St. Louis, MO 63110, 314.7475368, fullerb@wustl.edu.

This work was performed at Washington University School of Medicine in St. Louis.

Address for reprints: Brian M. Fuller, MD, MSCI, 660 South Euclid Avenue, Campus Box 8072, St. Louis, MO 63110. Reprints will not be ordered.

### Author Contributions

BMF: conception and study design, acquisition of data, analysis and interpretation of data, drafting and revising the manuscript, statistical expertise; RDP: study design, analysis and interpretation of data, drafting and revising the manuscript; NMM: study design, analysis and interpretation of data, drafting and revising the manuscript, statistical expertise; BWR: study design, analysis and interpretation of data, drafting and revising the manuscript, statistical expertise; BF: conception and study design, acquisition of data, analysis and interpretation of data, drafting and revising the manuscript; JY: study conception, analysis and interpretation of data, drafting and revising the manuscript; TS: acquisition of data, interpretation of data, drafting and revising the manuscript; NJJ: study design, interpretation of data, drafting and revising the manuscript; BED: study design, interpretation of data, drafting and revising the manuscript; EA: study design, analysis and interpretation of data, drafting and revising the manuscript; AMD: study design, analysis and interpretation of data, drafting and revising the manuscript; BTW: study design, analysis and interpretation of data, drafting and revising the manuscript; YY: conception and study design, analysis and interpretation of data, drafting and revising the manuscript, statistical expertise; CRC: conception and study design, analysis and interpretation of data, drafting and revising the manuscript; MHK: study design, analysis and interpretation of data, drafting and revising the manuscript; MSA: study design, analysis and interpretation of data, drafting and revising the manuscript.

All authors have read and given final approval of the submitted manuscript. BMF takes responsibility for the manuscript as a whole.

**Nicholas J. Johnson, MD,**

Departments of Emergency Medicine and Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington/Harborview Medical Center, 325 9<sup>th</sup> Avenue, Seattle, WA 98104

**Brian E. Driver, MD,**

Department of Emergency Medicine, University of Minnesota School of Medicine, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, Minnesota 55415

**Enyo Ablordeppey, MD, MPH,**

Departments of Emergency Medicine and Anesthesiology, Division of Critical Care, Washington University School of Medicine in St. Louis, St. Louis, MO 63110

**Anne M. Drewry, MD, MSCI,**

Department of Anesthesiology, Division of Critical Care Medicine, Washington University School of Medicine in St. Louis

**Brian T. Wessman, MD,**

Departments of Emergency Medicine and Anesthesiology, Division of Critical Care, Washington University School of Medicine in St. Louis, St. Louis, MO 63110

**Yan Yan, MD, MA, MHS, PH.D [Professor of Clinical Epidemiology and Biostatistics],**

Division of Public Health Sciences, Department of Surgery, Division of Biostatistics, Washington University School of Medicine, 418E, 2nd floor, 600 South Taylor Ave., St. Louis, MO 63110

**Marin H. Kollef, MD,**

Department of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63110

**Christopher R. Carpenter, MD, MSc, FACEP, AGSF,**

Department of Emergency Medicine, Washington University in St. Louis School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110

**Michael S. Avidan, MBBCh**

Department of Anesthesiology, Washington University in St. Louis School of Medicine

**Abstract**

**Objectives:** In mechanically ventilated patients, awareness with paralysis (AWP) can have devastating consequences, including post-traumatic stress disorder (PTSD), depression, and thoughts of suicide. Single-center data from the emergency department (ED) demonstrate an event rate for AWP factors higher than that reported from the operating room. However, there remains a lack of data on AWP among critically ill, mechanically ventilated patients. The objective was to assess the proportion of ED patients experiencing AWP and investigate modifiable variables associated with its occurrence.

**Design:** An *a priori* planned secondary analysis of a multicenter, prospective, before-and-after clinical trial.

**Setting:** The ED of three academic medical centers.

**Patients:** Mechanically ventilated adult patients that received neuromuscular blockers.

**Interventions:** None

**Measurements and Main Results:** All data related to sedation and analgesia were collected. AWP was the primary outcome, assessed with the modified Brice questionnaire, and was independently adjudicated by three expert reviewers. Perceived threat, in the causal pathway for PTSD, was the secondary outcome. A total of 388 patients were studied. The proportion of patients experiencing AWP was 3.4% (n= 13), the majority of whom received rocuronium (n= 12/13; 92.3%). Among patients who received rocuronium, 5.5% (n= 12/230) experienced AWP, compared to 0.6% (n= 1/158) among patients who did not receive rocuronium in the ED [odds ratio, 8.64; 95% confidence interval (CI) 1.11 to 67.15]. Patients experiencing AWP had a higher mean (standard deviation) threat perception scale score, compared to patients without AWP [15.6 (5.8) vs. 7.7 (6.0),  $p < 0.01$ ].

**Conclusions:** AWP was present in a concerning proportion of mechanically ventilated ED patients, was associated with rocuronium exposure in the ED, and led to increased levels of perceived threat, placing patients at greater risk for PTSD. Studies that aim to further quantify AWP in this vulnerable population and eliminate its occurrence are urgently needed.

### Keywords

awareness with paralysis; emergency department; mechanical ventilation; neuromuscular blockers; sedation; post-traumatic stress disorder

## INTRODUCTION

In critically ill mechanically ventilated patients, awareness with recall of paralysis can cause intense fear, pain, feelings of impending death, and thoughts of suicide [1-6]. Long-term psychological consequences are common and include depression, anxiety, post-traumatic stress disorder (PTSD), and debilitating phobias [3, 4]. Awareness with paralysis (AWP) has been studied extensively in the operating room (OR), yet very little data exist from the emergency department (ED), where mechanical ventilation is delivered to hundreds of thousands of patients annually [3, 7-10].

Historical practice patterns related to management of sedation and neuromuscular blockade in the ED place patients at high risk for AWP. These include: 1) high frequency of neuromuscular blockade use in the ED, with an increase in use of longer-acting agents (e.g. rocuronium) [11, 12]; 2) under-dosing of intravenous analgesia and sedation [13-15]; 3) high proportion of patients that receive no sedation after intubation [12, 15-19]; 4) delays in provision of sedation after neuromuscular blockade [16, 19, 20]; and 5) inconsistent monitoring and documentation of sedation depth [12, 16, 21]. For these reasons, our research group conducted the ED-AWARENESS Study to estimate the frequency of AWP in mechanically ventilated ED patients and assess modifiable risk factors associated with its occurrence [22, 23]. AWP occurred in 2.9% of patients exposed to neuromuscular blockers (approximately 25 times higher than that in the OR), and was more common in patients receiving rocuronium. However, that study was single center, limiting generalizability. It also remains the only ED-based AWP study to rigorously assess and adjudicate awareness events in a fashion similar to large-scale trials from the OR [3, 24, 25]. Therefore, a

persistent knowledge gap with respect to AWP in mechanically ventilated ED patients remains.

To address some of these limitations and further report on this important patient-centered complication, we planned *a priori* to prospectively assess for AWP during the conduct of an ED-based clinical trial regarding targeted sedation in the post-intubation period [26]. The objectives of the current work were to: 1) further estimate the frequency of AWP in mechanically ventilated ED patients; 2) identify risk factors associated with AWP; and 3) compare perceived threat between patients experiencing AWP and those without the complication. We hypothesized that AWP would be associated with modifiable variables related to sedation and neuromuscular blockade in the ED, and perceived threat would be higher in patients with AWP.

## MATERIALS AND METHODS

### Study Setting and Design

This was an *a priori* planned secondary analysis of AWP events collected during the ED-SED Pilot Trial, a multicenter, prospective, before-and-after pilot and feasibility trial that examined the implementation and impact of ED-based targeted sedation for mechanically ventilated patients [26, 27]. The study was conducted at three academic, tertiary medical centers from September 2020 to August 2021. These results are reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement (Supplemental Digital Content 1). The study was approved with waiver of informed consent (Board Name: Human Research Protection Office; Approval Number: 201909100; Approval Date: July 1, 2020; Study Title: The ED-SED Pilot Trial). The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as most recently amended. The [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04410783) identifier is [NCT04410783](https://clinicaltrials.gov/ct2/show/study/NCT04410783). A detailed description of the trial protocol has been published, as have results of the primary analysis [26, 27].

### Participants

Consecutive mechanically ventilated ED patients were screened. Patients were eligible if they: 1) were age  $\geq$  18 years; 2) received mechanical ventilation in the ED via an endotracheal tube; and 3) received a neuromuscular blocker (i.e. during rapid sequence intubation or the post-intubation phase of care). Patients with missing data regarding the receipt of neuromuscular blockers (n= 16, majority intubated at transferring EDs) were included in the analysis. This was done because approximately 90% of ED patients receive neuromuscular blockers either for intubation or in the post-intubation phase of care; we therefore thought it reasonably safe to assume a neuromuscular blocker was given [12]. We also aimed to provide conservative estimates for AWP. The exclusion criteria were: 1) acute neurologic injury (acute ischemic stroke, intracranial hemorrhage, traumatic brain injury, sudden cardiac arrest, status epilepticus, fulminant hepatic failure, and drug overdose); 2) death or transition to comfort measures within 24 hours; 3) transfer from the ED directly to the OR; 4) transfer to another hospital; and 5) chronic/home mechanical ventilation.

## Assessments and Outcome Measures

Research Electronic Data Capture (REDCap) tools were used to collate and manage data, which were abstracted from the electronic medical record [28, 29]. Based on our prior work in mechanically ventilated ED patients, a data entry study manual was developed and used to train and guide team members in entering data from the medical record into REDCap [12, 16, 22, 23, 30-32]. Quality control was achieved with manual and automatic methods, examining for outliers, and by enforcing plausible reference ranges in REDCap fields. Prior to data analysis, all data was electronically validated to verify accuracy.

Demographics and baseline variables comprised age, sex, race, weight, comorbid conditions, vital signs, and pertinent laboratory variables. Process of care variables included location of intubation and indication for mechanical ventilation, ED length of stay, receipt of antibiotics, and vasopressor use. Illness severity was assessed with the modified Sequential Organ Failure Assessment (SOFA) score [33, 34].

All data related to sedation and analgesia in the ED were collected. This included induction agents and neuromuscular blockers given for intubation. Medications during the post-intubation phase of care included fentanyl, propofol, midazolam, dexmedetomidine, lorazepam, ketamine, etomidate, haloperidol, and neuromuscular blockers. Depth of sedation was recorded per existing scales at each site during the study period. This included the Richmond-Agitation Sedation Scale (RASS) or the Sedation-Agitation Scale (SAS). Deep sedation was defined as RASS of -3 to -5, or SAS of 1-3 [12, 35, 36].

AWP was the primary outcome. The modified Brice questionnaire was used to evaluate for AWP, as done in multiple studies from the OR and our prior ED-based work on AWP [3, 22-25, 37]. To be considered for a possible AWP event, patients had to report a memory of wakeful paralysis, which could have occurred after losing consciousness (i.e. waking up while under paralysis) or before unconsciousness (i.e. memory of paralysis during intubation). AWP was assessed by study team member after extubation, and occurred either before hospital discharge or via telephone follow up after discharge. Screening and adjudication of AWP was consistent with large clinical trials from the OR and our prior approach [22, 24, 25]. Three independent reviewers were provided questionnaire responses and reports of patients' experience. Important clinical information was also provided, including analgesia and sedation, neuromuscular blockers and their dose. Reviewers were also provided an instruction sheet of the standard operating procedures regarding adjudication of awareness events. Reviewers adjudicated events as definite AWP, possible AWP, or no AWP; when two or more reviewers were in agreement, the patient was adjudicated as having AWP or not [22, 24, 25]. In cases of no agreement (i.e. all reviewers held opposing views), an *a priori* plan for a fourth reviewer was in place, but was not needed. To distinguish between AWP and appropriate recall of memories, the ICU memory tool was combined with the Brice questionnaire during the assessment for AWP. The ICU Memory Tool is a previously-validated instrument used to assess recall of events in the critically ill [38-40]. The questionnaire used to assess for AWP and the adjudicator instruction sheet is provided in Supplemental Digital Content 2 and Supplemental Digital Content 3.

The secondary outcome of interest was perceived threat, the self-measured sense of personal vulnerability and life endangerment, and previously identified to be in the causal pathway for PTSD development [41-44]. It therefore serves as a link, or mediator, between AWP and long-term psychological morbidity. A previously validated measurement tool, on a scale of 0 to 21 with higher scores indicating greater threat, was used to assess this outcome [41, 44].

### Statistical Analysis

Descriptive statistics and frequency distributions were used to assess patient characteristics. Continuous variables were compared using independent samples *t*-test or Mann-Whitney *U* test, whereas categorical variables were compared using Chi-square or Fisher's exact test.

The proportion of patients with possible or definite AWP was used to calculate the primary outcome. To examine potential variables associated with AWP, a multivariable logistic regression model was used. In anticipation of a small number of events, we took several factors into consideration. First, any results from the model would be exploratory and hypothesis-generating. Second, we elected to use a parsimonious model and followed recommendations to select covariates *a priori*, based on prior knowledge [22, 45-47]. We therefore selected these predictors for the model: 1) illness severity (i.e. SOFA score); 2) ED exposure to rocuronium (during intubation or post-intubation period); 3) depth of ED sedation (deep versus light); and 4) age. Third, we used multivariable logistic regression with Firth's bias-reducing penalized likelihood method. Different from conventional maximum likelihood estimation, the Firth's log likelihood is penalized by the determinant of the information matrix, provides bias-reduction for a small number of events, and yields finite and consistent estimates even in the case of separation [48-57].

A link between AWP and perceived threat was also explored. We hypothesized that AWP would be associated with increased perceived threat, placing patients at greater risk for developing PTSD symptoms [22, 26]. To test the association between AWP and perceived threat we used multivariable linear regression. We again followed recommendations that covariates be selected for inclusion *a priori*, and adjusted our model for the following: 1) age; 2) illness severity; 3) prior history of psychiatric illness; and 4) indication for intubation (i.e. medical [reference] versus trauma) [42, 46, 47, 58-60]. Our model used conservative robust standard errors in order to reduce the risk of type I error.

Agreement among adjudicators of AWP events was assessed with two-way, random-effects, intraclass correlation coefficient per prior approach [22, 25]. All tests were two-tailed with an alpha of 0.05 to indicate statistical significance. Sample size rationale was based off of the parent trial [26]. Based on our prior work regarding AWP in mechanically ventilated ED patients, we were confident during the planning of the trial that enough AWP events would be detected in order to conduct analyses with sufficient precision [22, 23].

## RESULTS

### Study Population

One thousand three hundred and fifty-six patients were screened and 388 were included as the final study population (Figure 1). The baseline characteristics of the study cohort are



in Table 1. Baseline differences existed for several variables. Patients experiencing AWP in general were younger, and there were a greater proportion that were male, White, and with a history of alcohol abuse and psychiatric illness. In addition, AWP patients were less severely ill (i.e. lower SOFA score and need for vasopressors). Three hundred and sixty-four (93.8% of total cohort) patients had coronavirus (COVID)-19 test results available; 1/13 AWP patients (7.7%) tested positive for COVID, and 40/351 (11.4%) of the remainder of the cohort tested positive for COVID,  $p=0.68$ ).

## Main Results

Twenty (5.2%) of the 388 patients reported memory of wakeful paralysis and were assessed by independent adjudicators for potential AWP events. Clinical summaries for these 20 patients are provided in Supplemental Digital Content 4. The intraclass correlation coefficient (95% CI) between adjudicators was 0.65 (0.42 – 0.83). After adjudication, the proportion of patients experiencing AWP was 3.4% (13/388; 95% CI 1.8% to 5.7%). Clinical summaries and adjudication results for the 13 AWP patients are in Supplemental Digital Content 5. There were 58 (14.9%) patients that died in the hospital. The proportion of surviving patients experiencing AWP was 3.9% (13/330; 95% CI 2.1% to 6.6%). Data regarding analgesia, sedation, and neuromuscular blocker use in the ED are in Table 2. Three hundred seventy-two patients received neuromuscular blockers for rapid sequence intubation, and 16 during the post-intubation period. No significant differences existed between the two groups, except for rocuronium use. The majority of patients with AWP received rocuronium ( $n=12/13$ ; 92.3%). Among patients who received rocuronium, 5.5% ( $n=12/230$ ) experienced AWP, compared to 0.6% ( $n=1/158$ ) among patients who did not receive rocuronium in the ED [odds ratio, 8.64; 95% confidence interval (CI) 1.11 to 67.15].

The logistic regression model assessing for predictors of AWP is shown in Table 3. Exposure to rocuronium in the ED was a statistically significant predictor of AWP (adjusted odds ratio, 7.22; 95% CI, 1.39 – 37.58).

Threat perception scores differed significantly between the two groups. Patients experiencing AWP had higher mean (standard deviation) threat perception, when compared to patients without AWP [15.6 (5.8) vs. 7.7 (6.0),  $p < 0.01$ ], indicating a greater degree of perceived threat. In the multivariable model assessing the relationship between AWP and perceived threat (Table 4), AWP was a statistically significant predictor of greater perceived threat ( $\beta = 7.46$ ; 95% CI, 4.14 to 10.77).

## DISCUSSION

Prior ED-based sedation research demonstrated clinical practice patterns placing patients at high risk for AWP [12, 13, 15-20, 61]. Given this, the severe psychological trauma that can result from AWP, and the paucity of ED-based data, we previously conducted the ED-AWARENESS Study to rigorously assess this complication in mechanically ventilated ED patients [22, 23]. In that study, 2.9% of patients that were given neuromuscular blockers experienced AWP, with a higher proportion of AWP among patients exposed to rocuronium. Given the limitations of that single center study and to add to the body of research,

we conducted the current investigation in order to further assess AWP in this vulnerable population.

The first significant finding is that the proportion of patients experiencing AWP was 3.4%; when restricted to survivors, this proportion was 3.9%. This rate is similar to that observed from the ED-AWARENESS study, as well as a comprehensive systematic review and meta-analysis regarding AWP in mechanically ventilated patients in the ED and ICU [22, 62]. Patient testimonials reflect vivid recollections of pain from procedures, being restrained, and feelings of impending death. Data from the OR estimate the prevalence of AWP during general anesthesia to be approximately 1-2/1000 cases (0.1-0.2%), and approximately 0.9% in high-risk patients managed with total intravenous anesthesia [3, 8, 9, 63]. While more work is needed, as the study of AWP in mechanically ventilated ED patients is in its relative infancy, these event rates are concerning and could translate into approximately 10,000 cases of AWP annually in the United States.

Another important finding relates to rocuronium exposure in the ED, as it was significantly higher among patients with AWP as compared to those not experiencing the complication. Longer-acting neuromuscular blockers are a known risk for AWP [2, 3, 8, 64]. The current results are also congruent with the higher rates of rocuronium use in AWP patients observed in the ED-AWARENESS Study [22]. Given the similar methodology of the two studies, combining the results demonstrates that AWP among patients given rocuronium was 5.4% (n= 19/354), compared to 1.0% (n= 4/417) among patients who did not receive rocuronium in the ED [odds ratio, 5.86; 95% CI, 1.97 – 17.40] [22, 26]. These results are even more critical when considering that rocuronium use for rapid sequence intubation in the ED has increased from less than 10% to around 50% over the last two decades [11, 12, 65, 66]. Further, the use of rocuronium in the ED has been shown to reduce the chance that patients will ever receive post-intubation sedation [67]. If sedation is received in the context of rocuronium use, data demonstrate that it is at lower doses and in delayed fashion [19, 20]. Our results call further attention to the need for: 1) patient-centered clinical outcomes when studying endotracheal intubation and mechanical ventilation in the ED; 2) improved monitoring of both the brain and the effects of neuromuscular blockade (e.g. train-of-four monitoring); and 3) pragmatic interventions to prevent AWP [68]. While rocuronium has high rates of first-pass success during intubation, our data indicate a need to look beyond short-term surrogate outcomes if the human cost is AWP and commensurate long-term psychological morbidity [69].

The final important finding relates to the psychological footprint from AWP. Patients with AWP had higher degrees of perceived threat, and AWP strongly influenced levels of threat in multivariable analysis. This is important as perceived threat is a strong mediator for development of PTSD as it relates to medical emergencies [43, 44, 59, 70, 71]. These findings objectively demonstrate the psychological vulnerability as a result of AWP and lend weight to the call for AWP in mechanically ventilated ED patients to be a never event [69]. However, as PTSD was not formally assessed in this cohort, future studies will need to confirm this link between AWP, perceived threat, and PTSD.



This report has multiple strengths, including the rigorous methodology in the assessment of AWP and the multicenter approach. However, several limitations exist. The sample size is the largest to date with respect to AWP among mechanically ventilated ED patients, yet remains small, and there were only 13 events for the primary outcome. This is reflected in the wide confidence intervals of our analyses, and draws attention to the need for larger studies. The small number of events also brings concern for statistical overfitting, which we attempted to mitigate by using a parsimonious approach and small sample methodology (Firth's bias-reducing penalized likelihood method). Definite and possible AWP was combined, which could inflate the event rate. This approach is consistent with large trials from the OR, and our prior work, both of which demonstrate similar distress and perceived threat among those with possible or definite events [22, 24]. The multicenter approach enhances external validity, but extrapolating these findings beyond our three sites may not be valid. Further, rocuronium use was high in the current investigation, and results may not extend to other sites where longer-acting neuromuscular blockers are given less frequently. However, our data are consistent with the well-established trend of increased rocuronium use in the ED. In addition, because reviewers were not blinded to data regarding neuromuscular blockers and sedation, it is possible that the adjudication process was biased against rocuronium (i.e. more AWP adjudicated in patients with known rocuronium exposure). While our methodology in adjudicating AWP events is rigorous and consistent with prior approach, subjectivity exists. Because of this, our adjudicators were given instructions to assure uniformity, however subjectivity in determining real memories from perceptions or delusions (e.g. hallucinations, medication effects) remains. In addition, given the variability in lengths of stay and ventilator duration experienced by mechanically ventilated patients, the exact timing of questionnaire administration was not standardized, which could impact reproducibility. However, our event rate for AWP is consistent with prior work, lending face validity to the results [22, 62]. Also, the Brice questionnaire has not been extensively used outside of the operating room setting, and its sensitivity may vary among the critically ill. Our consistent results with prior work, rigorous adjudication methodology, and use of the ICU Memory Tool to attempt to separate memories from AWP events lend confidence in the results. Recognizing that patients must survive to extubation to be assessed for AWP, for the primary analysis we elected to include those patients that died in the hospital in the denominator. This was in effort to prioritize cautious estimates, and again highlights the need for larger studies in the ED population. Finally, this was a secondary analysis of a previously conducted clinical trial. While all parts of the current investigation were planned *a priori*, these results should be viewed as hypothesis-generating.

## CONCLUSIONS

AWP was present in almost 4% of survivors of ED-based mechanical ventilation, was associated with rocuronium exposure in the ED, and led to increased levels of perceived threat, placing patients at greater risk for PTSD. Studies that aim to further quantify AWP in this vulnerable population and eliminate its occurrence are urgently needed.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Conflicts of Interest and Sources of Funding

BMF is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) under award number R34HL150404. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. MHK is supported by the Barnes-Jewish Hospital Foundation. Funders played no role in the following features of the study: study design, data collection, data management, data analysis, data interpretation, writing of the manuscript or decision to submit the manuscript for publication.

All authors report no conflicts of interest.

## REFERENCES

1. Cook T, Andrade J, Bogod D, Hitchman J, Jonker W, Lucas N et al. 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: patient experiences, human factors, sedation, consent, and medicolegal issues. *British Journal of Anaesthesia* 2014, 113(4):560–574. [PubMed: 25204696]
2. Pandit J, Andrade J, Bogod D, Hitchman J, Jonker W, Lucas N et al. 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: summary of main findings and risk factors. *British Journal of Anaesthesia* 2014, 113(4):549–559. [PubMed: 25204697]
3. Avidan MS, Mashour GA. Prevention of Intraoperative Awareness with Explicit Recall Making Sense of the Evidence. *The Journal of the American Society of Anesthesiologists* 2013, 118(2):449–456.
4. Leslie K, Chan MT, Myles PS, Forbes A, McCulloch TJ. Posttraumatic stress disorder in aware patients from the B-aware trial. *Anesthesia & Analgesia* 2010, 110(3):823–828. [PubMed: 19861364]
5. Schwender D, Kunze-Kronawitter H, Dietrich P, Klasing S, Forst H, Madler C. Conscious awareness during general anaesthesia: patients' perceptions, emotions, cognition and reactions. *British Journal of Anaesthesia* 1998, 80(2):133–139. [PubMed: 9602573]
6. Finlay T, Parke T. Awareness in the emergency department: A patient's story. *Journal of the Intensive Care Society* 2016, 17(2):175–177. [PubMed: 28979484]
7. Easter BD, Fischer C, Fisher J. The use of mechanical ventilation in the ED. *The American Journal of Emergency Medicine* 2012, 30(7):1183–1188. [PubMed: 22100473]
8. Sandin RH, Enlund G, Samuelsson P, Lennmarken C. Awareness during anaesthesia: a prospective case study. *The Lancet* 2000, 355(9205):707–711.
9. Sebel PS, Bowdle TA, Ghoneim MM, Rampil IJ, Padilla RE, Gan TJ et al. The incidence of awareness during anesthesia: a multicenter United States study. *Anesthesia & Analgesia* 2004, 99(3):833–839. [PubMed: 15333419]
10. Wunsch H, Linde-Zwirble WT, Angus DC, Hartman ME, Milbrandt EB, Kahn JM. The epidemiology of mechanical ventilation use in the United States. *Critical Care Medicine* 2010, 38(10):1947–1953. [PubMed: 20639743]
11. Brown CA, Bair AE, Pallin DJ, Walls RM, Investigators NI. Techniques, success, and adverse events of emergency department adult intubations. *Annals of Emergency Medicine* 2015, 65(4):363–370. e361. [PubMed: 25533140]
12. Fuller BM, Roberts BW, Mohr NM, Knight IV WA, Adeoye O, Pappal RD et al. The ED-SED Study: A Multicenter, Prospective Cohort Study of Practice Patterns and Clinical Outcomes Associated With Emergency Department SEDation for Mechanically Ventilated Patients. *Critical Care Medicine* 2019, 47(11):1539–1548. [PubMed: 31393323]
13. Traylor BR, Patanwala AE, Sakles JC, Erstad BL. Under-dosing of etomidate for rapid sequence intubation in the emergency department. *Current drug safety* 2013, 8(4):253–256. [PubMed: 23909706]
14. Bhat R, Goyal M, Graf S, Bhooshan A, Teferra E, Dubin J et al. Impact of post-intubation interventions on mortality in patients boarding in the emergency department. *Western Journal of Emergency Medicine* 2014, 15(6):708. [PubMed: 25247049]

15. Bonomo JB, Butler AS, Lindsell CJ, Venkat A. Inadequate provision of postintubation anxiolysis and analgesia in the ED. *The American Journal of Emergency Medicine* 2008, 26(4):469–472. [PubMed: 18410818]
16. Stephens RJ, Ablordeppey E, Drewry AM, Palmer C, Wessman BT, Mohr NM et al. Analgosedation practices and the impact of sedation depth on clinical outcomes among patients requiring mechanical ventilation in the ED: a cohort study. *Chest* 2017, 152(5):963–971. [PubMed: 28645462]
17. Weingart GS, Carlson JN, Callaway CW, Frank R, Wang HE. Estimates of sedation in patients undergoing endotracheal intubation in US EDs. *The American Journal of Emergency Medicine* 2013, 31(1):222–226. [PubMed: 22770915]
18. Nengchu P. Reducing the risk of inadequate sedation during rapid sequence intubation in the emergency department setting. *J Am Pharm Assoc* 2014, 54:e217.
19. Korinek JD, Thomas RM, Goddard LA, St John AE, Sakles JC, Patanwala AE. Comparison of rocuronium and succinylcholine on postintubation sedative and analgesic dosing in the emergency department. *European Journal of Emergency Medicine* 2014, 21(3):206–211. [PubMed: 23510899]
20. Watt JM, Amini A, Traylor BR, Amini R, Sakles JC, Patanwala AE. Effect of paralytic type on time to post-intubation sedative use in the emergency department. *Emergency Medicine Journal* 2013, 30(11):893–895. [PubMed: 23139098]
21. Steel TL, Lokhandwala S, Caldwell ES, Johnson NJ, Miller CD, Gong MN et al. Variability in Sedation Assessment among Intubated Patients in the Emergency Department. *Academic Emergency Medicine* 2021:10.1111/acem.14259.
22. Pappal RD, Roberts BW, Mohr NM, Ablordeppey E, Wessman BT, Drewry AM et al. The ED-AWARENESS Study: A Prospective, Observational Cohort Study of Awareness With Paralysis in Mechanically Ventilated Patients Admitted From the Emergency Department. *Annals of Emergency Medicine* 2021, 77(5):532–544. [PubMed: 33485698]
23. Pappal RD, Roberts BW, Mohr NM, Ablordeppey E, Wessman BT, Drewry AM et al. Protocol for a prospective, observational cohort study of awareness in mechanically ventilated patients admitted from the emergency department: the ED-AWARENESS Study. *BMJ Open* 2019, 9(10):e033379.
24. Avidan MS, Jacobsohn E, Glick D, Burnside BA, Zhang L, Villafranca A et al. Prevention of intraoperative awareness in a high-risk surgical population. *New England Journal of Medicine* 2011, 365(7):591–600. [PubMed: 21848460]
25. Avidan MS, Zhang L, Burnside BA, Finkel KJ, Searleman AC, Selvidge JA et al. Anesthesia awareness and the bispectral index. *New England Journal of Medicine* 2008, 358(11):1097–1108. [PubMed: 18337600]
26. Fuller BM, Roberts BW, Mohr NM, Pappal RD, Stephens RJ, Yan Y et al. A study protocol for a multicentre, prospective, before-and-after trial evaluating the feasibility of implementing targeted SEDation after initiation of mechanical ventilation in the emergency department (The ED-SED Pilot Trial). *BMJ Open* 2020, 10(12):e041987.
27. Fuller BM, Roberts BW, Mohr NM, Faine B, Drewry AM, Wessman BT et al. The Feasibility of Implementing Targeted SEDation in Mechanically Ventilated Emergency Department Patients: The ED-SED Pilot Trial. *Critical Care Medicine* 2022: .
28. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L et al. The REDCap consortium: Building an international community of software platform partners. *Journal of biomedical informatics* 2019, 95:103208. [PubMed: 31078660]
29. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of biomedical informatics* 2009, 42(2):377–381. [PubMed: 18929686]
30. Fuller BM, Ferguson IT, Mohr NM, Drewry AM, Palmer C, Wessman BT et al. Lung-protective ventilation initiated in the emergency department (LOV-ED): a quasi-experimental, before-after trial. *Ann Emerg Med* 2017, 70(3):406–418. [PubMed: 28259481]
31. Fuller BM, Ferguson IT, Mohr NM, Drewry AM, Palmer C, Wessman BT et al. A quasi-experimental, before-after trial examining the impact of an emergency department mechanical

- ventilator protocol on clinical outcomes and lung-protective ventilation in acute respiratory distress syndrome. *Crit Care Med* 2017, 45(4):645–652. [PubMed: 28157140]
32. Fuller BM, Mohr NM, Miller CN, Deitchman AR, Levine BJ, Castagno N et al. Mechanical Ventilation and ARDS in the ED: A Multicenter, Observational, Prospective, Cross-sectional Study. *Chest* 2015, 148(2):365–374. [PubMed: 25742126]
  33. Vincent J, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. *Intensive care medicine* 1996, 22:707–710. [PubMed: 8844239]
  34. Vincent J-L, De Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. *Critical care medicine* 1998, 26(11):1793–1800. [PubMed: 9824069]
  35. Reade MC, Finfer S. Sedation and delirium in the intensive care unit. *New England Journal of Medicine* 2014, 370(5):444–454. [PubMed: 24476433]
  36. Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B et al. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. *American journal of respiratory and critical care medicine* 2012, 186(8):724–731. [PubMed: 22859526]
  37. Brice D, Hetherington R, Utting J. A simple study of awareness and dreaming during anaesthesia. *BJA: British Journal of Anaesthesia* 1970, 42(6):535–542. [PubMed: 5423844]
  38. Jones C, Griffiths RD, Humphris G, Skirrow PM. Memory, delusions, and the development of acute posttraumatic stress disorder-related symptoms after intensive care. *Critical Care Medicine* 2001, 29(3):573–580. [PubMed: 11373423]
  39. Samuelson K, Lundberg D, Fridlund B. Stressful memories and psychological distress in adult mechanically ventilated intensive care patients—a 2-month follow-up study. *Acta Anaesthesiologica Scandinavica* 2007, 51(6):671–678. [PubMed: 17567267]
  40. Svenningsen H. Associations between sedation, delirium and post-traumatic stress disorder and their impact on quality of life and memories following discharge from an intensive care unit. *Danish Medical Journal* 2013, 60(4):B4630–B4630. [PubMed: 23651729]
  41. Cornelius T, Agarwal S, Garcia O, Chaplin W, Edmondson D, Chang BP. Development and validation of a measure to assess patients' threat perceptions in the emergency department. *Academic Emergency Medicine* 2018, 25(10):1098–1106. [PubMed: 29972892]
  42. Heir T, Blix I, Knatten CK. Thinking that one's life was in danger: perceived life threat in individuals directly or indirectly exposed to terror. *The British Journal of Psychiatry* 2016, 209(4):306–310. [PubMed: 27056624]
  43. Meli L, Kautz M, Julian J, Edmondson D, Sumner JA. The role of perceived threat during emergency department cardiac evaluation and the age-posttraumatic stress disorder link. *Journal of Behavioral Medicine* 2018, 41(3):357–363. [PubMed: 29188468]
  44. Moss J, Roberts MB, Shea L, Jones CW, Kilgannon H, Edmondson DE et al. Association between perceived threat and the development of posttraumatic stress disorder symptoms in patients with life-threatening medical emergencies. *Academic Emergency Medicine* 2020, 27(2):109–116. [PubMed: 31650652]
  45. Mashour G, Avidan M. Intraoperative awareness: controversies and non-controversies. *British Journal of Anaesthesia* 2015, 115(suppl\_1):i20–i26. [PubMed: 25735710]
  46. Leisman DE, Harhay MO, Lederer DJ, Abramson M, Adjei AA, Bakker J et al. Development and reporting of prediction models: guidance for authors from editors of respiratory, sleep, and critical care journals. *Critical Care Medicine* 2020, 48(5):623. [PubMed: 32141923]
  47. Maslove DM, Leisman DE. Causal inference from observational data: New guidance from pulmonary, critical care, and sleep journals. *Crit Care Med* 2019, 47(1):1–2. [PubMed: 30557240]
  48. Firth D Bias reduction of maximum likelihood estimates. *Biometrika* 1993:27–38.
  49. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. *Statistics in Medicine* 2002, 21(16):2409–2419. [PubMed: 12210625]
  50. Fazeli S, Snyder BS, Gareen IF, Lehman CD, Khan SA, Romanoff J et al. Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance

Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112). *JAMA Network Open* 2022, 5(5):e2210331–e2210331. [PubMed: 35536580]

51. Gasperi C, Hapfelmeier A, Schneider A, Kuhn KA, Donnachie E, Hemmer B. Association of pregnancies with risk of multiple sclerosis. *Multiple Sclerosis Journal* 2022;13524585221080542.
52. Mahnke AH, Roberts MH, Leeman L, Ma X, Bakhireva LN, Miranda RC. Prenatal opioid-exposed infant extracellular miRNA signature obtained at birth predicts severity of neonatal opioid withdrawal syndrome. *Scientific reports* 2022, 12(1):1–17. [PubMed: 34992227]
53. Papageorge MV, de Geus SW, Woods AP, Ng SC, McAneny D, Tseng JF et al. The Effect of Hospital Versus Surgeon Volume on Short-Term Patient Outcomes After Pancreaticoduodenectomy: a SEER–Medicare Analysis. *Annals of Surgical Oncology* 2022:1–8.
54. Saegerman C, Diep AN, Renault V, Donneau A-F, Stamatakis L, Coppieters W et al. A 2-month field cohort study of SARS-CoV-2 in saliva of BNT162b2 vaccinated nursing home workers. *Communications Medicine* 2022, 2(1):1–11. [PubMed: 35603280]
55. Peiper NC, Shamblen S, Gilbertson A, Guest G, Kopp M, Guy L et al. Acceptability of a HIV self-testing program among people who use illicit drugs. *International Journal of Drug Policy* 2022, 103:103613. [PubMed: 35255391]
56. Averbuch D, Moshkovitz L, Ilan S, Abu Ahmad W, Temper V, Strahilevitz J. Bacteremia with Carbapenemase-Producing Enterobacterales in Immunocompromised Patients Colonized with These Bacteria. *Microbial Drug Resistance* 2022, 28(5):593–600. [PubMed: 35580283]
57. Kwok WC, Ma TF, Chan JWM, Pang HH, Ho JCM. A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity. *BMC Pulmonary Medicine* 2022, 22(1):1–9. [PubMed: 34980061]
58. Holbrook TL, Hoyt DB, Stein MB, Sieber WJ. Perceived threat to life predicts posttraumatic stress disorder after major trauma: risk factors and functional outcome. *Journal of Trauma and Acute Care Surgery* 2001, 51(2):287–293.
59. Moss J, Roberts MB, Shea L, Jones CW, Kilgannon H, Edmondson DE et al. Healthcare provider compassion is associated with lower PTSD symptoms among patients with life-threatening medical emergencies: a prospective cohort study. *Intensive Care Medicine* 2019:1–8.
60. Zhu DR, Julian J, Lee SJ, Thanataveerat A, Sumner JA. Patterns of peritraumatic threat perceptions in patients evaluated for suspected acute coronary syndrome according to prior and current posttraumatic stress symptoms. *General hospital psychiatry* 2018, 53:119–124. [PubMed: 29789141]
61. Bhat R, Mazer-Amirshahi M, Sun C, Vaughns J, Dynin M, Tefera E et al. Accuracy of rapid sequence intubation medication dosing in obese patients intubated in the ED. *The American journal of emergency medicine* 2016, 34(12):2423–2425. [PubMed: 27727068]
62. Pappal RD, Roberts BW, Winkler W, Yaegar LH, Stephens RJ, Fuller BM. Awareness With Paralysis in Mechanically Ventilated Patients in the Emergency Department and ICU: A Systematic Review and Meta-Analysis. *Critical Care Medicine* 2021, 49(3):e304–e314. [PubMed: 33566462]
63. Zhang C, Liang X, Sun Y-x, LI Y-h, Zhang L, Feng C-s et al. Bispectral index monitoring prevent awareness during total intravenous anesthesia: a prospective, randomized, double-blinded, multi-center controlled trial. *Chinese medical journal* 2011, 124(22):3664–3669. [PubMed: 22340221]
64. Ghoneim MM, Block RI, Haffarnan M, Mathews MJ. Awareness during anesthesia: risk factors, causes and sequelae: a review of reported cases in the literature. *Anesthesia & Analgesia* 2009, 108(2):527–535. [PubMed: 19151283]
65. Sagarin MJ, Barton ED, Chng Y-M, Walls RM, Investigators NEAR. Airway management by US and Canadian emergency medicine residents: a multicenter analysis of more than 6,000 endotracheal intubation attempts. *Annals of emergency medicine* 2005, 46(4):328–336. [PubMed: 16187466]
66. April MD, Arana A, Pallin DJ, Schauer SG, Fantegrossi A, Fernandez J et al. Emergency department intubation success with succinylcholine versus rocuronium: a National Emergency Airway Registry study. *Annals of emergency medicine* 2018, 72(6):645–653. [PubMed: 29747958]

67. Lembersky O, Golz D, Kramer C, Fantegrossi A, Carlson JN, Walls RM et al. Factors associated with post-intubation sedation after emergency department intubation: A Report from The National Emergency Airway Registry. *The American journal of emergency medicine* 2020, 38(3):466–470. [PubMed: 31130369]
68. Tasaka CL, Duby JJ, Pandya K, Wilson MD, Hardin KA. Inadequate sedation during therapeutic paralysis: use of bispectral index in critically ill patients. *Drugs-real world outcomes* 2016, 3(2):201–208. [PubMed: 27398299]
69. Gottlieb M, Carlson JN. Speechless: Awareness With Recall of Paralysis in the Emergency Department Setting. *Annals of Emergency Medicine* 2021, 77(5):545–546. [PubMed: 33454139]
70. Davydow DS, Zatzick D, Hough CL, Katon WJ. A longitudinal investigation of posttraumatic stress and depressive symptoms over the course of the year following medical–surgical intensive care unit admission. *General hospital psychiatry* 2013, 35(3):226–232. [PubMed: 23369507]
71. Wiedemar L, Schmid J-P, Müller J, Wittmann L, Schnyder U, Saner H et al. Prevalence and predictors of posttraumatic stress disorder in patients with acute myocardial infarction. *Heart & lung* 2008, 37(2):113–121. [PubMed: 18371504]



**KEY POINTS****Question:**


What is the proportion of ED patients that experience awareness with paralysis (AWP) and do modifiable variables associated with its occurrence exist?

**Findings:**

In this pre-planned secondary analysis of a multicenter, prospective, before-after clinical trial, 3.4% of patients experienced AWP. Rocuronium was used in 12/13 (92.3%) patients and was independently associated with AWP. AWP patients experienced higher levels of perceived threat, placing them at increased risk for post-traumatic stress disorder.

**Meaning:**

These findings suggest that AWP is present in a concerning proportion of mechanically ventilated ED patients and should be targeted for prevention.



**Figure 1.**  
Study flow diagram

**Table 1.**

Characteristics of included study participants.

Baseline Characteristics	All Subjects (n = 388)	Patients with AWP (n = 13)	Patients without AWP (n = 375)
Age (years)	60 (45 – 72)	51 (46 – 58)	60 (45 – 72)
Female, n (%)	148 (38.1)	3 (23.1)	145 (38.7)
BMI	27.7 (23.9 – 33.8)	29.0 (23.3 – 37.0)	27.7 (23.8 – 33.7)
Race, n (%)			
White	190 (49.0)	11 (84.6)	179 (47.7)
Black	154 (39.7)	1 (7.7)	153 (40.8)
Hispanic	30 (7.7)	1 (7.7)	29 (7.7)
Asian	9 (2.3)	0 (0.0)	9 (2.4)
Native American	2 (0.5)	0 (0.0)	2 (0.5)
Other	3 (0.8)	0 (0.0)	3 (0.8)
Comorbidities, n (%)			
Dementia	17 (4.4)	0 (0.0)	17 (4.5)
Diabetes Mellitus	116 (29.9)	3 (23.1)	113 (30.1)
Cirrhosis	25 (6.4)	1 (7.7)	24 (6.4)
Heart Failure	83 (21.4)	2 (15.4)	81 (21.6)
ESRD	13 (3.4)	0 (0.0)	13 (3.5)
COPD	81 (20.9)	3 (23.1)	78 (20.8)
Immunosuppression	28 (7.2)	1 (7.7)	27 (7.2)
Malignancy	51 (13.1)	1 (7.7)	50 (13.3)
Alcohol Abuse	51 (13.1)	5 (38.5)	46 (12.3)
Psychiatric <sup>a</sup>	97 (25.0)	6 (46.2)	91 (24.3)
Intubation Data, n (%)			
Location of Intubation			
Emergency Department	321 (82.7)	9 (69.2)	312 (83.2)
Transferring Facility	42 (10.8)	2 (15.4)	40 (10.7)
Prehospital	25 (6.4)	2 (15.4)	23 (6.1)
Indication for Intubation			
Trauma	81 (20.9)	3 (23.1)	78 (20.8)
Medical	307 (79.1)	10 (76.9)	297 (79.2)
Temperature (°C)	36.6 (36.1 – 37.1)	36.9 (36.5 – 37.6)	36.6 (36.0 – 37.1)
Mean Arterial Pressure (mmHg)	98.8 (24.3)	104.8 (27.9)	98.8 (24.2)
Lactate (mmol/L)	2.7 (1.5 – 4.8)	1.8 (1.6 – 4.1)	2.7 (1.5 – 4.8)
SOFA	4.0 (3.0 – 7.0)	3.0 (2.0 – 4.0)	4.0 (3.0 – 7.0)
ED Process of Care Variables			
Length of Stay (hours)	5.8 (3.9 – 8.7)	4.9 (2.6 – 12.4)	5.8 (3.9 – 8.6)
Vasopressor Infusion, n (%)	150 (38.7)	2 (15.4)	148 (39.5)
Blood transfusion, n (%)	47 (12.1)	3 (23.1)	44 (11.7)
Central venous catheter, n (%)	105 (27.1)	4 (30.8)	101 (26.9)

Baseline Characteristics	All Subjects (n = 388)	Patients with AWP (n = 13)	Patients without AWP (n = 375)
Antibiotics, n (%)	198 (51.0)	4 (30.8)	194 (51.7)

AWP = awareness with paralysis; BMI = body mass index; ESRD = end stage renal disease; COPD = chronic obstructive pulmonary disease; SOFA = Sequential Organ Failure Assessment; ED = emergency department

<sup>a</sup>Psychiatric if diagnosed with schizophrenia, bipolar, major depression, or generalized anxiety disorder

Continuous variables are reported as mean (standard deviation) and median (interquartile range).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2.** Data regarding analgesia, sedation, and neuromuscular blocker use in the emergency department.

Variable	All Subjects (n = 388)	Patients with AWP (n = 13)	Patients without AWP (n = 375)	Odds Ratio or Between-Group Difference <sup>a</sup> (95% CI)
<i>RSI Variables*</i>				
Etomidate, n (%)	235 (60.6)	8 (61.5)	227 (60.5)	1.04 (0.34-3.25)
Dose (mg)	20 (20 - 30)	20 (20 - 30)	20 (20 - 30)	0.26 (-7.51 to 8.04)
Weight-Based Dose (mg/kg)	0.27 (0.21 - 0.32)	0.29 (0.18 - 0.31)	0.26 (0.22 - 0.32)	-0.02 (-0.11 to 0.07)
Ketamine, n (%)	131 (33.8)	5 (38.5)	126 (33.6)	1.24 (0.40-3.85)
Dose (mg)	100 (100 - 150)	100 (62 - 155)	100 (100 - 150)	-11.9 (-60.0 - 36.0)
Weight-Based Dose (mg/kg)	1.30 (1.09 - 1.66)	0.85 (0.59 - 1.79)	1.30 (1.10 - 1.66)	-0.37 (-0.98 - 0.23)
Succinylcholine, n (%)	155 (39.9)	3 (23.1)	152 (40.5)	0.44 (0.12-1.63)
Dose (mg)	100 (100 - 120)	125 (100 - NA)	100 (100 - 120)	15.5 (-33.7 to 64.6)
Weight-Based Dose (mg/kg)	1.32 (1.12 - 1.51)	1.11 (0.85 - NA)	1.32 (1.14 - 1.52)	-0.24 (-0.77 to 0.28)
Rocuronium, n (%)	217 (55.9)	10 (76.9)	207 (55.2)	2.71 (0.73-9.99)
Dose (mg)	100 (100 - 100)	100 (100 - 110)	100 (100 - 100)	3.2 (-14.2 to 20.5)
Weight-Based Dose (mg/kg)	1.17 (1.00 - 1.39)	1.06 (0.92 - 1.34)	1.17 (1.0 - 1.39)	-0.08 (-0.31 to 0.16)
<i>ED Post-Intubation Variables</i>				
Fentanyl, n (%)	331 (85.3)	12 (92.3)	319 (85.1)	2.11 (0.27 - 16.5)
Cumulative Dose (mcg)	400 (200 - 750)	338 (125 - 763)	400 (200 - 750)	-25 (-281 to 231)
Weight-Based Dose (mcg/kg)	5.0 (2.0 - 9.1)	3.5 (1.4 - 9.3)	5.2 (2.0 - 9.1)	-1.0 (-4.34 to 2.27)
Propofol, n (%)	304 (78.4)	10 (76.9)	294 (78.4)	0.92 (0.25 - 3.42)
Cumulative Dose (mg)	248 (38 - 663)	252 (42 - 1457)	248 (37 - 659)	200 (-141 to 543)
Weight-Based Dose (mg/kg)	3.2 (0.6 - 8.1)	3.6 (0.6 - 13.4)	3.0 (0.6 - 8.1)	1.2 (-2.1 to 4.4)
Midazolam, n (%)	96 (24.7)	4 (30.8)	92 (24.5)	1.37 (0.41 - 4.54)
Cumulative Dose (mg)	6.0 (4.0 - 10.0)	5.0 (2.0 - 5.8)	7.0 (4.0 - 10.0)	-4.8 (-15.9 to 6.2)
Weight-Based Dose (mg/kg)	0.07 (0.04 - 0.14)	0.05 (0.02 - 0.06)	0.07 (0.04 - 0.14)	-0.07 (-0.24 to 0.10)
Dexmedetomidine, n (%)	37 (9.5)	1 (7.7)	36 (9.6)	0.79 (0.10 - 6.21)
Cumulative Dose (mg)	1.5 (0.4 - 3.2)	0.40 (NA)	1.5 (0.4 - 3.3)	-1.7 (-6.7 to 3.4)
Weight-Based Dose (mg/kg)	0.02 (0.01 - 0.04)	0.004 (NA)	0.02 (0.01 - 0.04)	-0.02 (-0.09 to 0.04)

Variable	All Subjects (n = 388)	Patients with AWP (n = 13)	Patients without AWP (n = 375)	Odds Ratio or Between-Group Difference <sup>a</sup> (95% CI)
Lorazepam, n (%)	20 (5.2)	1 (7.7)	19 (5.1)	1.56 (0.19 – 12.64)
Cumulative Dose (mg)	2.0 (1.0 – 2.0)	1.0 (NA)	2.0 (1.0 – 2.0)	-1.3 (-5.0 to 2.4)
Weight-Based Dose (mg/kg)	0.03 (0.01 - 0.04)	0.01 (NA)	0.03 (0.01 - 0.04)	-0.02 (-0.07 to 0.03)
Ketamine, n (%)	41 (10.6)	2 (15.4)	39 (10.4)	1.57 (0.34 – 7.33)
Cumulative Dose (mg)	100 (40 - 200)	75 (50 – NA)	100 (40 - 200)	-83 (-301 to 137)
Weight-Based Dose (mg/kg)	1.25 (0.40 – 2.63)	0.65 (0.45 – NA)	1.34 (0.38 – 2.65)	-1.05 (-3.08 to 0.98)
Rocuronium <sup>b</sup> , n (%)	16 (4.1)	2 (15.4)	14 (3.7)	4.69 (0.95 – 23.19)
Cumulative Dose (mg)	100 (53 - 100)	100 (100 - NA)	100 (50 - 100)	10 (-64 to 83)
Weight-Based Dose (mg/kg)	0.87 (0.63 – 1.08)	0.88 (0.85 – NA)	0.86 (0.58 – 1.14)	-0.06 (-0.94 to 0.82)
<i>Sedation Depth Variables</i> <sup>**</sup>				
Median RASS in ED	-2 (-3 to 0)	-2 (-3 to -1)	-2 (-3 to 0)	-0.3 (-2.3 to 1.6)
Median SAS in ED	2 (1 - 3)	3 (2 - 4)	2 (1 - 3)	0.5 (-0.6 to 1.7)
Deep Sedation, n (%)	194 (50.0)	7 (53.8)	187 (49.9)	1.17 (0.39 – 3.56)

AWP = awareness with paralysis, CI = confidence interval, RSI = rapid sequence intubation, ED = emergency department, RASS = Richmond Agitation-Sedation Scale; SAS = Sedation-Agitation Scale

\* 3 total patients were given midazolam and 6 were given propofol (no difference between groups). Data not shown due to space constraints.

\*\* 823 sedation assessments were performed in the ED, on average 2.1 assessments per patient.

<sup>a</sup> Odds ratio is presented for binary data and between-group difference is presented as the difference in means for the continuous data.

<sup>b</sup> Refers to paralytic given as additional bolus after RSI

Continuous variables are reported as median (interquartile range).



Multivariable logistic regression model with Firth’s bias-reducing penalized likelihood method for small sample sizes. Awareness with paralysis is the dependent variable.

**Table 3.**

Variables	aOR	95% CI	p
Rocuronium exposure in the ED <sup>a</sup>	7.22	1.39 - 37.58	0.02
Age	0.99	0.96 - 1.02	0.33
SOFA Score	0.80	0.63 - 1.02	0.07
ED deep sedation	1.13	0.39 - 3.25	0.83

aOR = adjusted odds ratio, CI = confidence interval, ED = emergency department, SOFA = Sequential Organ Failure Assessment

<sup>a</sup>Includes rapid sequence intubation and the post-intubation phase of care

Multivariable linear regression model assessing the relationship between awareness with paralysis and perceived threat.

**Table 4.**

Variable	Regression Coefficients	95% CI	<i>p</i>
Awareness with paralysis	7.46	4.14 – 10.77	<0.01
Age	-0.08	-0.13 to -0.03	<0.01
SOFA	0.16	-0.15 to 0.46	0.31
History of psychiatric illness <sup>a</sup>	1.59	-0.23 to 3.41	0.09
Indication for intubation	-1.71	-3.66 to 0.24	0.09

SOFA = Sequential Organ Failure Assessment

<sup>a</sup>Includes schizophrenia, bipolar, major depression, or generalized anxiety disorder